1.Chang TE, Huang YS, Chang CH, Perng CL, Huang YH, Hou MC. The susceptibility of anti-tuberculosis drug induced liver injury and chronic hepatitis C infection: A systematic review and meta-analysis. J Chin Med Assoc. 2018; 81: 111-118.

2.Chang TE, Huang YS, Su WJ, Perng CL, Huang YH, Hou MC. The role of regular liver function monitoring in antituberculosis drug induced liver injury. J Chin Med Assoc. 2019; 82: 535-540. 

3.Chang TE, Huang YS, Perng CL, Huang YH, Hou MC. Use of proton pump inhibitors and the risk of hepatocellular carcinoma: A systematic review and meta-analysis. J Chin Med Assoc. 2019; 82: 756-761.

4.Chang TE, Luo JC, Yang UC, Huang YH, Hou MC, Lee FY. Fecal microbiota profile in patients with inflammatory bowel disease in Taiwan. J Chin Med Assoc. 2021; 84: 580-587 

5.Chang TE, Su CW, Huang YS, Huang YH, Hou MC, Wu JC. Hepatitis D virus dual infection increased the risk of hepatocellular carcinoma compared with hepatitis B virus mono infection: A meta-analysis. J Chin Med Assoc. 2022; 85: 30-41.

6.Chang TE, Lee KC, Lee PC, Wang YP, Lin YT, Huang HC, Luo JC, Ho HL, Huang YH, Hou MC; Task Force for Precision Medicine in Gut Microbial Therapy. Assuring safety of fecal microbiota transplantation in the COVID-19 era: A single-center experience. JGH Open. 2023; 7: 765-771.

7.Chang TE, Huang KH, Luo JC, Huang YH, Lin HH, Fang WL, Hou MC. The alteration of fecal microbial and metabolic profile of gallstone patients in Taiwan: Single-center study. J Chin Med Assoc. 2024; 87: 572-580.